Aligning with Toshiba, Abbott Nearly Completes its Diagnostics Line
A market leader in most diagnostic technology categories, immunoassay, hematology, and blood glucose, Abbott has historically stumbled in clinical chemistry. But with customers wanting broader options from fewer suppliers, Abbott knew it had to make its move in chemistry. Earlier in 1997, it bought Alcyon Analyzer, a small French company. But with this deal with Toshiba, Abbott is poised to make a major move.
You may also be interested in...
The findings of the Cumberlege Review into how safety issues for three medical product groups were handled will shape debate on the UK’s new devices legislation, now going through parliament. The MHRA’s devices regulatory activity also comes in for scrutiny.
Medical device companies – including Sientra, Endologix and Invacare – won loans from the US government’s Paycheck Protection Program, intended to protect jobs during the coronavirus pandemic. In total, nearly 1,400 device makers collected as much as $1.6bn, according to a Medtech Insight analysis of PPP data.
A damning UK report makes uncomfortable reading about how thousands of women suffered avoidable harm from the anti-epileptic drug sodium valproate and two other medical interventions and how safety concerns raised were dismissed, overlooked and ignored.